



(12) **United States Patent**
Lulla et al.

(10) **Patent No.:** **US 9,259,428 B2**
(45) **Date of Patent:** ***Feb. 16, 2016**

(54) **COMBINATION OF AZELASTINE AND FLUTICASONE FOR NASAL ADMINISTRATION**
(71) Applicant: **Cipla Limited, Mumbai (IN)**
(72) Inventors: **Amar Lulla, Mumbai (IN); Geena Malhotra, Mumbai (IN)**
(73) Assignee: **Cipla Limited, Mumbai (IN)**
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

3,557,162 A 1/1971 Lens et al.
3,639,434 A 2/1972 Oxley et al.
3,755,302 A 8/1973 Ercoli et al.
3,813,384 A 5/1974 Vogelsang et al.
3,828,080 A 8/1974 Phillipps et al.
3,856,828 A 12/1974 Phillipps et al.
3,891,631 A 6/1975 Phillipps et al.
3,981,894 A 9/1976 Phillipps et al.
3,989,686 A 11/1976 Phillipps et al.
4,093,721 A 6/1978 Phillipps et al.
4,113,680 A 9/1978 Kamano et al.
4,187,301 A 2/1980 Edwards
4,188,385 A 2/1980 Edwards
4,198,403 A 4/1980 Alvarez
4,221,787 A 9/1980 Bodor et al.
4,261,984 A 4/1981 Alvarez
4,263,289 A 4/1981 Edwards
4,267,173 A 5/1981 Draper
4,285,937 A 8/1981 Kalvoda
4,310,466 A 1/1982 Edwards
4,335,121 A 6/1982 Phillipps et al.
4,377,575 A 3/1983 Stache et al.
4,472,393 A 9/1984 Shapiro
4,607,028 A 8/1986 Schmidlin
4,710,495 A 12/1987 Bodor
4,861,765 A 8/1989 Mitsukuchi et al.
4,992,474 A 2/1991 Skidmore et al.
4,994,439 A 2/1991 Longenecker et al.
4,996,335 A 2/1991 Bodor
5,063,222 A 11/1991 Komoto et al.
5,081,113 A 1/1992 Claussner et al.
5,086,050 A 2/1992 Hetteche et al.
5,164,194 A 11/1992 Hetteche

(21) Appl. No.: **14/661,720**

(22) Filed: **Mar. 18, 2015**

(65) **Prior Publication Data**
US 2015/0190405 A1 Jul. 9, 2015

Related U.S. Application Data

(60) Continuation of application No. 14/539,646, filed on Nov. 12, 2014, which is a continuation of application No. 13/644,127, filed on Oct. 3, 2012, now Pat. No. 8,937,057, which is a continuation of application No. 12/508,388, filed on Jul. 23, 2009, now Pat. No. 8,318,709, which is a division of application No. 10/518,016, filed as application No. PCT/GB03/02557 on Jun. 13, 2003, now Pat. No. 8,168,620.

(51) **Int. Cl.**
A61K 31/56 (2006.01)
A61K 9/00 (2006.01)
A61K 31/55 (2006.01)
A61K 31/573 (2006.01)
A61K 31/58 (2006.01)
A61K 47/10 (2006.01)
A61K 47/18 (2006.01)
A61K 47/26 (2006.01)
A61K 47/38 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/56** (2013.01); **A61K 9/0043** (2013.01); **A61K 31/55** (2013.01); **A61K 31/573** (2013.01); **A61K 31/58** (2013.01); **A61K 47/10** (2013.01); **A61K 47/183** (2013.01); **A61K 47/186** (2013.01); **A61K 47/26** (2013.01); **A61K 47/38** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

2,837,464 A 6/1958 Nobile
3,067,197 A 12/1962 Agnello et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 2003244799 B2 12/2003
BE 889563 A1 11/1981
DE 1059906 B 6/1959
DE 2164058 A1 7/1972
DE 3836579 A1 5/1989
DE 19947234 A1 4/2001
DE 10152369 A1 5/2002
EP 0004773 A2 10/1979
EP 0057401 A1 8/1982
EP 0179583 A1 4/1986

(Continued)

OTHER PUBLICATIONS

European Search Report dated May 12, 2009, EP 09075101, 2 pages.
(Continued)

Primary Examiner — Robert A Wax
Assistant Examiner — Thor Nielsen
(74) *Attorney, Agent, or Firm* — Conley Rose, P.C.; Rodney B. Carroll

(57) **ABSTRACT**

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,202,316 A 4/1993 Claussner et al.
 5,232,919 A 8/1993 Scheffler et al.
 5,271,946 A 12/1993 Hettche
 5,362,721 A 11/1994 Stache et al.
 5,420,120 A 5/1995 Boltralik
 5,608,093 A 3/1997 Stache et al.
 5,658,549 A 8/1997 Akehurst et al.
 5,658,919 A 8/1997 Ratnaraj et al.
 5,707,984 A 1/1998 Tjoeng et al.
 5,830,490 A 11/1998 Weinstein et al.
 5,837,699 A 11/1998 Sequeira et al.
 5,849,265 A 12/1998 Li-Bovet et al.
 5,889,015 A 3/1999 Sequeira et al.
 5,914,122 A 6/1999 Otterbeck et al.
 5,972,920 A 10/1999 Seidel
 5,981,517 A 11/1999 Bodor
 6,017,963 A 1/2000 Alfonso et al.
 6,057,307 A 5/2000 Sequeira et al.
 6,127,353 A 10/2000 Yuen et al.
 6,136,294 A 10/2000 Adjei et al.
 6,197,761 B1 3/2001 Biggadike et al.
 6,241,969 B1 6/2001 Saidi et al.
 6,261,539 B1 7/2001 Adjei et al.
 6,294,153 B1 9/2001 Modi
 6,319,513 B1 11/2001 Dobrozsi
 6,330,938 B1 12/2001 Hervé et al.
 6,391,340 B1 5/2002 Malmqvist-Granlund et al.
 6,395,300 B1 5/2002 Straub et al.
 6,416,743 B1 7/2002 Fassberg et al.
 6,537,983 B1 3/2003 Biggadike et al.
 6,583,180 B2 6/2003 Link et al.
 6,750,210 B2 6/2004 Biggadike
 6,759,398 B2 7/2004 Biggadike
 6,777,399 B2 8/2004 Biggadike et al.
 6,777,400 B2 8/2004 Biggadike et al.
 6,787,532 B2 9/2004 Biggadike et al.
 6,835,724 B2 12/2004 Stache et al.
 6,858,593 B2 2/2005 Biggadike et al.
 6,858,596 B2 2/2005 Biggadike et al.
 6,878,698 B2 4/2005 Biggadike et al.
 6,881,423 B2 4/2005 Dohi et al.
 6,921,757 B2 7/2005 Cuenoud et al.
 7,101,866 B2 9/2006 Biggadike et al.
 7,125,985 B2 10/2006 Biggadike et al.
 7,132,532 B2 11/2006 Biggadike et al.
 7,144,845 B2 12/2006 Biggadike et al.
 7,214,672 B2 5/2007 Komoto et al.
 7,244,742 B2 7/2007 Pieper et al.
 7,288,536 B2 10/2007 Biggadike et al.
 7,291,608 B2 11/2007 Biggadike et al.
 7,291,609 B2 11/2007 Biggadike et al.
 7,405,206 B2 7/2008 Biggadike et al.
 7,498,321 B2 3/2009 Biggadike et al.
 7,524,970 B2 4/2009 John
 7,531,528 B2 5/2009 Biggadike et al.
 7,541,350 B2 6/2009 Biggadike et al.
 7,579,335 B2 8/2009 Biggadike et al.
 7,592,329 B2 9/2009 Biggadike et al.
 7,629,335 B2 12/2009 Biggadike et al.
 7,638,508 B2 12/2009 Biggadike et al.
 7,776,315 B2 8/2010 Pairet et al.
 8,071,073 B2 12/2011 Dang et al.
 8,163,723 B2 4/2012 Lulla et al.
 8,168,620 B2 5/2012 Lulla et al.
 8,304,405 B2 11/2012 Lulla et al.
 8,318,709 B2 11/2012 Lulla et al.
 8,933,060 B2 1/2015 Lulla et al.
 8,937,057 B2 1/2015 Lulla et al.
 2002/0061281 A1 5/2002 Osbakken et al.
 2002/0076382 A1 6/2002 Kaplan et al.
 2002/0081266 A1 6/2002 Woolfe et al.
 2003/0018019 A1 1/2003 Meade et al.
 2004/0136918 A1 7/2004 Garrett et al.

2004/0242638 A1 12/2004 Yanni et al.
 2005/0163724 A1 7/2005 Miyadai et al.
 2005/0192261 A1 9/2005 Jost-Price et al.
 2006/0002861 A1 1/2006 Biggadike
 2006/0228306 A1 10/2006 Lane
 2007/0020330 A1 1/2007 Dang et al.
 2009/0124585 A1 5/2009 Cross et al.
 2009/0156567 A1 6/2009 Biggadike
 2009/0286762 A1 11/2009 Myles et al.
 2010/0152147 A1 6/2010 Fuge et al.
 2010/0311706 A1 12/2010 Biggadike et al.
 2012/0065177 A1 3/2012 Myles et al.
 2015/0072010 A1 3/2015 Lulla et al.

FOREIGN PATENT DOCUMENTS

EP 0393658 B1 10/1990
 EP 0416951 A1 3/1991
 EP 0780127 A1 6/1997
 EP 1519731 B1 4/2009
 EP 2072051 A1 6/2009
 EP 2075000 A1 7/2009
 GB 1191965 5/1970
 GB 1296458 11/1972
 GB 1384372 2/1975
 GB 1438940 6/1976
 GB 1517278 7/1978
 GB 2079755 A 1/1982
 GB 2088877 A 6/1982
 GB 2140800 A 12/1984
 GB 2389530 A 12/2003
 IL 109656 A 2/1998
 JP 4208267 A 7/1992
 JP 8291072 A 11/1996
 JP 8291073 A 11/1996
 JP 200253485 A 2/2002
 WO 8504589 A1 10/1985
 WO 8903390 A1 4/1989
 WO 9015816 A1 12/1990
 WO 9104252 A1 4/1991
 WO 9214472 A1 9/1992
 WO 9531964 A1 11/1995
 WO 9619199 A1 6/1996
 WO 9632151 A1 10/1996
 WO 9701337 A1 1/1997
 WO 9705136 A1 2/1997
 WO 9715298 A1 5/1997
 WO 9721721 A1 6/1997
 WO 9721724 A1 6/1997
 WO 9724365 A1 7/1997
 WO 9731626 A1 9/1997
 WO 9740836 A1 11/1997
 WO 9746243 A1 12/1997
 WO 9817676 A1 4/1998
 WO 9834596 A2 8/1998
 WO 9848839 A1 11/1998
 WO 9901467 A2 1/1999
 WO 9925359 A1 5/1999
 WO 9932089 A1 7/1999
 WO 0016814 A1 3/2000
 WO 0033892 A1 6/2000
 WO 0038811 A1 7/2000
 WO 0048587 A1 8/2000
 WO 0049993 A2 8/2000
 WO 0066522 A1 11/2000
 WO 0104118 A2 1/2001
 WO 01020331 A1 3/2001
 WO 0154481 A2 8/2001
 WO 0154664 A1 8/2001
 WO 0157025 A1 8/2001
 WO 0162722 A2 8/2001
 WO 0178736 A1 10/2001
 WO 0178739 A1 10/2001
 WO 0178741 A1 10/2001
 WO 0178745 A1 10/2001
 WO 0200199 A1 1/2002
 WO 0200679 A2 1/2002

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	0208243	A1	1/2002
WO	0211711	A2	2/2002
WO	0212265	A1	2/2002
WO	0212266	A1	2/2002
WO	0213868	A1	2/2002
WO	0226723	A1	4/2002
WO	0236106	A2	5/2002
WO	02051422	A1	7/2002
WO	02053186	A2	7/2002
WO	02066422	A1	8/2002
WO	02070490	A1	9/2002
WO	02076933	A1	10/2002
WO	02085296	A2	10/2002
WO	02088167	A1	11/2002
WO	02100879	A1	12/2002
WO	03000241	A2	1/2003
WO	03013427	A2	2/2003
WO	03033000	A1	4/2003
WO	03035668	A2	5/2003
WO	03040691	A2	5/2003
WO	03042229	A1	5/2003
WO	03042230	A1	5/2003
WO	03048181	A1	6/2003
WO	03062259	A2	7/2003
WO	03064445	A1	8/2003
WO	03066033	A1	8/2003
WO	03066036	A1	8/2003
WO	03066656	A1	8/2003
WO	03072592	A1	9/2003
WO	03086399	A1	10/2003
WO	03105856	A1	12/2003
WO	2004013156	A1	2/2004
WO	2004019955	A1	3/2004
WO	2005005451	A1	1/2005
WO	2005005452	A1	1/2005
WO	2006058022	A1	6/2006
WO	2007061454	A1	5/2007
WO	2008012338	A2	1/2008
WO	2008012338	A3	1/2008
ZA	872389		4/1987

OTHER PUBLICATIONS

Settipane, Guy, et al., "Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study," *Clinical Therapeutics*, 1995, vol. 17, No. 2, pp. 252-263.

Shapiro, Elliot L., et al., "17 heteroaroyl esters of corticosteroids 2. 11 β -hydroxy series," *Journal of Medicinal Chemistry*, vol. 30, No. 9, 1987, pp. 1581-1588, American Chemical Society.

Shapiro, Elliot, et al., "17-esters and 17,21-diester of 9- α , 11- β -dichlorocorticoids. Synthesis and anti-inflammatory activity," *Steroids*, vol. 9, No. 2, pp. 143-156, Feb. 1967.

Shapiro, Elliot L., et al., "Synthesis and structure-activity studies of corticosteroid 17-heterocyclic aromatic esters. 1. 9 α ,11 β -dichloro series," *Journal of Medicinal Chemistry*, vol. 30, No. 6, pp. 1068-1073, 1987, American Chemical Society.

Shenfield, Gillian M., "Fixed drug combinations: which ones can be recommended?" *Current Therapeutics*, Dec. 1986, pp. 15, 16, 22-24, 27-29.

Simpson, Richard J., "Budesonide and terfenadine, separately and in combination, in the treatment of hay fever," *Annals of Allergy*, Dec. 1994, vol. 73, pp. 497-502 plus cover and publication pages, American College of Allergy and Immunology.

Smith, Carolyn L., et al., "In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids," *Arzneim-Forsch./Drug Res.*, 1998, vol. 48 (II), No. 9, pp. 956-959.

Smith, N., et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary

Souness, et al., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors," *Immunopharmacology*, 2000, vol. 47, pp. 127-162, Elsevier Science B.V.

Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," *J Allergy Clin Immunol*, 1999, vol. 103, No. 3, Part 2, pp. S386-S387, Mosby, Inc.

Study No. 03DMW062—"Pharmacokinetics of GW685698X and CCI18781 (fluticasone propionate) when co-administered by the intratracheal or intravenous route to the anaesthetised white pig," 2004, 21 pages.

Study No. B30947—"The Pharmacokinetics of GW685698X and CCI18781 following intratracheal co-administration to the anaesthetised white pig," 2003, 20 pages.

Szefer, Stanley J., et al., Chapter 21, "Glucocorticoids in severe asthma: mechanisms of action and route of administration," *Difficult Asthma*, pp. 371-375, Martin Dunitz Ltd, 1999.

Tanaka, Akira, et al., "Synthesis of 4H-furo[3,2-b]indole derivatives. III (1). Preparation of 4H-furo[3,2-b]indole-2-carboxylic acid derivatives," vol. 16, pp. 785-788, Jun. 1979, HeteroCorporation.

The United States Pharmacopoeia, 23rd Edition, U.S. Pharmacopoeia Convention, Inc., 1995, pp. 1843-1844, "Physical Tests / X-ray Diffraction (941)."

Ueno, Hiroaki, et al., "Synthesis and evaluation of antiinflammatory activities of a series of corticosteroid 17 α -esters containing a functional group," *Journal of Medicinal Chemistry*, vol. 34, No. 8, 1991, pp. 2468-2473.

Van As, Andre, et al., "Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate," *J. Allergy Clin. Immunol.*, 1993, vol. 91, No. 6, pp. 1146-1154.

Van Bavel, J. H., et al., "Ocular efficacy and clinician overall evaluation of intranasal fluticasone propionate (FP) versus loratadine (LOR) in seasonal allergic rhinitis (SAR)," *Annals of Allergy, Asthma, & Immunology*, 1997, vol. 78, p. 128, Abstract P101.

Van Der Molen, T., et al., "Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids," *Thorax*, vol. 52, 1996, pp. 535-539 plus information page.

Vanrell, Herrero, "Preservatives in ophthalmic formulations: an overview," *Arch Soc Esp Oftalmol*, 2007, vol. 82, pp. 531-532.

Veramyst™ (fluticasone furoate) Nasal Spray, GlaxoSmithKline, Apr. 2007, Summary Sheet, pp. 1-20.

Wang, De-Yun, "Treatment of Allergic Rhinitis: H1-Antihistamines and Intranasal Steroids," *Current Drug Targets—Inflammation & Allergy*, 2002, vol. 1, pp. 215-220, Bentham Science Publishers Ltd.

Westlund, Ronald, et al., "Fluticasone propionate aqueous nasal spray 200 mg once daily provides relief of ocular symptoms associated with seasonal allergic rhinitis," 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, Mar. 16-21, 2001, Abstract No. 522, 1 page.

World Review 2001: The Pharmaceutical Market, vol. 1 International, IMS Health, 2001, cover, preface, and copyright pages plus pp. 4-42 and 5-1 through 5-11, IMS A.G.

Foreign communication from a related counterpart application—Pre-Grant Opposition, 1696/MUMNP/2009, Jun. 27, 2012, 124 pages. PCT/GB01/03495, International Search Report, Oct. 17, 2001, 2 pages.

PCT/GB01/03495, International Preliminary Examination Report, Aug. 30, 2002, 11 pages.

PCT/EP2007/057695, International Search Report and Written Opinion, Oct. 28, 2008, 16 pages.

PCT/EP2007/057695, International Preliminary Report on Patentability, Feb. 3, 2009, 8 pages.

Document submitted in the Opposition proceedings regarding European Patent No. 1519731, D35, Units and Sales for Corticosteroids in 2009 and 2010, Oct. 5, 2011, 3 pages.

Document submitted in the Opposition proceedings regarding European Patent No. 1519731, D36, Stability tests, Oct. 5, 2011, 4 pages.

Office Action dated Jul. 11, 2011—20632 IL, 3 pages.

(56)

References Cited

OTHER PUBLICATIONS

Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

European Search Report dated May 12, 2009, EP 09075100, 3 pages.

Sandham, David A., et al., "Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters," *Bioorganic & Medicinal Chemistry*, 2004, vol. 12, pp. 5213-5224, Elsevier Ltd.

Scadding, Glenis K., et al., "Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis," *Rhinology*, 1991, Suppl. 11, pp. 37-43.

Schmidt, Bernhard M. W., et al., "The New Topical Steroid Ciclesonide is Effective in the Treatment of Allergic Rhinitis," *Journal of Clinical Pharmacology*, 1999, vol. 39, pp. 1062-1069, American College of Clinical Pharmacology.

Ong, John T. H., et al., "Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide," *Arch Dermatol*, vol. 125, Dec. 1989, pp. 1662-1665.

Ong, John T. H., et al., "Micellar solubilization of timobesone acetate in aqueous and aqueous propylene glycol solutions of nonionic surfactants," *Pharmaceutical Research*, vol. 5, No. 11, 1988, pp. 704-708, Plenum Publishing Corporation.

Omrust, Susan B., et al., "Mometasone furoate: a review of its intranasal use in allergic rhinitis," *Drugs*, vol. 56, No. 4, Oct. 1998, pp. 725-745, Adis International Limited.

Opponent's submission dated Oct. 6, 2011 to European Patent No. 1519731, 2 pages.

Opponent's submission dated Sep. 23, 2011 regarding additional documents on European Patent No. 1519731, 2 pages.

Opponent's submission dated Sep. 23, 2011 regarding list of attendees at oral proceedings on European Patent No. 1519731, 1 page.

Patentee's response of Sep. 6, 2010 of European Patent No. 1519731, 49 pages.

Opposition to EP 1519731, Aug. 8, 2011, 19 pages.

Patentee's submission dated Sep. 19, 2011 on European Patent No. 1519731, 1 page.

Patentee's submission dated Sep. 29, 2011 regarding list of attendees at oral proceedings on EP Patent No. 1519731, 1 page.

Phillipps, Gordon H., et al., "Synthesis and structure—activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane—17 β -carbothioates and—17 β -carbosenoates," *Journal of Medicinal Chemistry*, 1994, vol. 37, No. 22, pp. 3717-3729, American Chemical Society.

Popper, Thomas L., et al., "Structure-activity relationships of a series of novel topical corticosteroids," *J. steroid Biochem.*, 1987, vol. 27, No. 4-6, pp. 837-843, Pergamon Journals Ltd.

Portmann, D. et al., "Acceptability of local treatment of allergic rhinitis with a combination of a corticoid (beclomethasone) and an antihistaminic (azelastine)," XP-002252974, 2000, 1 page, Medline.

Pre-Grant Opposition, Indian Patent Application 2092/KOLNP/2007 dated Jun. 8, 2007, 183 pages.

Prescribing Information for ASTEPRO®, Nov. 2010, 20 pages, Meda Pharmaceuticals Inc.

Prescribing Information for RHINOCORT AQUA®, Dec. 2010, 32 pages, AstraZeneca LP.

Preservative, definition of. Composite definition of preservative in the Medical dictionary, from internet site <http://medical-dictionary.thefreedictionary.com/preservative>, Nov. 4, 2009, 3 pages.

Product Information Rhinocort Aqua® (budesonide) Nasal Spray 32 mcg, Jan. 2005, 2 pages.

Product Information, Nasonex® (mometasone furoate monohydrate) Nasal Spray 50 mcg, Aug. 2001, 22 pages, Schering Corporation.

Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-SPEC-02/09.RS, Feb. 2009, 2 pages, FMC Corporation.

Rapid Response Report: Summary with Critical Appraisal, "Fluticasone Furoate versus Fluticasone Propionate for Seasonal Allergic Rhinitis: A Review of the Clinical and Cost Effectiveness," Jun. 13, 2011, 8 pages, Canadian Agency for Drugs and Technologies in Health.

Ratner, Paul H., et al., "A Comparison of the Efficacy of Fluticasone Propionate Aqueous Nasal Spray and Loratadine, Alone and in Combination, for the Treatment of Seasonal Allergic Rhinitis," *The Journal of Family Practice*, Aug. 1998, vol. 47, No. 2, pp. 118-125 plus cover and publishing pages, Appleton & Lange.

Ratner, Paul H., et al., "Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis," *Annals of Allergy, Asthma & Immunology*, Jan. 2008, vol. 100, pp. 74-81.

Reddy, Indra K., "Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach," 1996, pp. 382-385 plus cover and publishing pages, Technomic Publishing Company, Inc.

Result of oral proceedings dated Oct. 12, 2011 of EP Patent No. 1519731, 5 pages.

Safety Data Sheet No. 110536, Jun. 23, 2008, Version 13, Beconase Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.

Safety Data Sheet No. 110556, Jul. 4, 2008, Version 14, Flonase Nasal Spray, 5 pages, GlaxoSmithKline.

Sakagami, Masahiro, et al., "Mucoadhesive BDP microspheres for powder inhalation—their unique pharmacokinetic-pharmacodynamic profiles," *Respiratory Drug Delivery*, vol. VI, pp. 193-199, 1998.

Salib, Rami Jean, et al., "Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis," *Drug Safety*, 2003, vol. 26, No. 12, pp. 863-893 plus cover and publishing pages, ADIS Data Information BV.

Baldwin C. M., et al., abstract, "Mometasone furoate: a review of its intranasal use in allergic rhinitis," 2008, 1 page, [Drugs, pp. 1723-1739, vol. 68, No. 12].

Bielory, L., et al., "Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis," *Allergy*, 2011, pp. 686-693, vol. 66, John Wiley & Sons A/S.

ClinicalTrials.gov, "A study of the effectiveness and safety of mometasone furoate nasal spray (MFNS, SCH032088) for the treatment of nasal polyps (P05604)," <http://clinicaltrials.gov/ct2/show/NCT01386125>, Mar. 14, 2013, 3 pages, Merck.

ClinicalTrials.gov, "Mometasone furoate nasal spray for treatment of nasal polyposis after surgery (study P03218)," <http://clinicaltrials.gov/ct2/show/NCT00731185>, Aug. 7, 2008, 3 pages, Schering-Plough.

Makihara, Seiichiro, et al., "Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: a randomized placebo-controlled trial," *Allergology International*, 2012, pp. 295-304, vol. 61, No. 2, Japanese Society of Allergology.

Small, Catherine Butkus, et al., "Efficacy and safety of mometasone furoate nasal spray in nasal polyposis," *J Allergy Clin Immunol*, Dec. 2005, pp. 1275-1281, American Academy of Allergy, Asthma and Immunology.

Stjärne, Pär, et al., "Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery," *Arch Otolaryngol Head Neck Surg*, Mar. 2009, pp. 296-302, vol. 135, No. 3, American Medical Association.

Vuralcan, Erkan, et al., "Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps," 2012, pp. 5-10, vol. 6, No. 1, Therapeutic Advances in Respiratory Disease.

Office communication dated Jul. 6, 2011 (3 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

Office Action dated Jul. 15, 2013 (48 pages), U.S. Appl. No. 13/204,978, filed Aug. 8, 2011.

ClinicalTrials.gov, "Efficacy and safety of mometasone furoate plus azelastine HCl combination versus mometasone furoate alone or azelastine alone in patients with perennial allergic rhinitis (NCT01470053)," <http://clinicaltrials.gov/ct2/show/NCT01470053>, Aug. 26, 2013, 3 pages, Hanlim Pharm. Co., Ltd.

1 page summary of "Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the

(56)

References Cited

OTHER PUBLICATIONS

- Finn, Jr., A. F., et al., 1 page abstract of "Efficacy of three different dosing regimens of fluticasone propionate (FP) aqueous nasal spray in the treatment of perennial nonallergic rhinitis (PNAR)," *J Allergy Clin Immunol*, Jan. 1997, Ref. No. 1787.
- Graft, David, et al., "A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray," *J Allergy Clin Immunol*, Oct. 1996, pp. 724-731, vol. 98, No. 4, Mosby-Year Book, Inc.
- Marazzi, P., et al., 1 page abstract of "Prophylactic use of once-daily mometasone furoate (Nasonex) aqueous nasal spray in patients with seasonal allergic rhinitis," *J Allergy Clin Immunol*, Jan. 1997, Ref. No. 1789.
- Nakabayashi, S., et al., 1 page abstract of "The effect of initial treatment by FP aqueous nasal spray in patients with Japanese cedar pollinosis," Sep. 1996, vol. 99, No. 9, pp. 1162-1171.
- Simon, Michael W., 1 page abstract of "The efficacy of azelastine in the prophylaxis of acute upper respiratory tract infections," *Allergy & Immunology*, Dec. 2003, vol. 16, No. 4, pp. 275-282.
- Trangsrud, Amanda J., et al., "Intranasal corticosteroids for allergic rhinitis," *Pharmacotherapy*, 2002, vol. 22, No. 11, 14 pages, Pharmacotherapy Publications.
- Yamagishi, Masuo, et al., 1 page abstract of "Azelastine in the treatment and prevention of seasonal grass pollinosis," *Practica Oto-Rhino-Laryngologica*, 1991, pp. 1345-1353, vol. 84, No. 9.
- "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008," *European Journal of Allergy and Clinical Immunology*, Apr. 2008, 162 pages, vol. 63, No. 86, Wiley-Blackwell, Copenhagen, Denmark.
- Aria Workshop Report entitled "Allergic Rhinitis and its Impact on Asthma," *The Journal of Allergy and Clinical Immunology*, Nov. 2001, 205 pages, vol. 108, No. 5, Mosby.
- Astelin Product Information, Jul. 2011, 8 pages, Meda Pharmaceuticals Inc.
- Berger, William E., et al., "Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis," *Annals of Allergy, Asthma & Immunology*, Jun. 1999, pp. 535-541, vol. 82.
- Communication of Notice of Opposition in a foreign counterpart application, European Patent No. 2072051, Nov. 6, 2014, 19 pages.
- Comparative Composition data of Azelastine with steroids table filed by patentee, 20632A-EP, Nov. 2, 2010, 2 pages.
- European Sales Data Table, 2001-2005, 3 pages.
- Nasacort® AQ (triamcinolone acetonide) Product Leaflet, Nov. 2010, 5 pages, sanofi-aventis U.S. LLC.
- Opponent/Appellant's Statement of Grounds of Appeal against the Interlocutory Decision in Opposition Proceedings in a foreign counterpart application, European Patent No. 1 519 731 B1, May 28, 2012, 62 pages.
- Pawankar, Ruby, "Allergic Rhinitis and Its Impact on Asthma: An Evidence-Based Treatment Strategy for Allergic Rhinitis," *Asian Pacific Journal of Allergy and Immunology*, Mar. 2002, pp. 43-52 plus 1 page publishing information, vol. 20, No. 1, Allergy, Asthma and Immunology Society of Thailand.
- Reichmuth, Daniel, et al., "Present and Potential Therapy for Allergic Rhinitis," *BioDrugs*, Dec. 2000, pp. 371-387, vol. 14, No. 6, Adis International Limited.
- Reply of Patentee to Grounds of Appeal in a foreign counterpart application, European Patent No. 1 519 731 B1, Feb. 14, 2013, 46 pages.
- Rote Liste® catalog of drugs marketed in Germany in the year 2002, entries 07 079 and 07 080 (Allergodil, nasal spray (solution)), and 72 025 (Nasonex, nasal spray (suspension)), 3 pages, Rote Liste® Service GmbH, Frankfurt.
- Scadding, G. K., "Clinical assessment of antihistamines in rhinitis," Stricker, W. E., et al., "Fluticasone Propionate Aqueous Nasal Spray (FP) and Loratadine (LOR), Alone and in Combination, in the Treatment of Fall Seasonal Allergic Rhinitis (SAR)," Ref. No. P62, Jan. 1998, p. 115, vol. 80.
- Sur, Denise K., et al., "Treatment of Allergic Rhinitis," *American Family Physician*, Jun. 15, 2010, pp. 1440-1446, vol. 81, No. 12, American Academy of Family Physicians.
- USP Monographs: Flunisolide Nasal Solution, 2013, 2 pages, USPC.
- Lieberman, Phil, "Treatment Update: Nonallergic Rhinitis," *Allergy and Asthma Proceedings*, Jul.-Aug. 2001, pp. 199-202, vol. 22, No. 4.
- Van Cauwenberge, P., et al., "Consensus statement on the treatment of allergic rhinitis," *Allergy*, 2000, pp. 116-134, vol. 55, Munksgaard, United Kingdom.
- "Nasal Polyp," Wikipedia entry, http://en.wikipedia.org/wiki/Nasal_polyp, downloaded from Internet on Apr. 3, 2013, 4 pages.
- Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma," <http://www.medscape.com/viewarticle/406237> print, [*Clin Drug Invest*, vol. 21, No. 9, 2001, pp. 633-642], Adis International Limited.
- Johnson, Malcom, "Development of fluticasone propionate and comparison with other inhaled corticosteroids," *J Allergy Clin Immunol*, Apr. 1998, vol. 101, No. 4, Part 2, pp. S434-S439, Mosby, Inc.
- Juniper, E. F., et al., "Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis," *Journal of Allergy and Clinical Immunology*, Mar. 1989, vol. 83, No. 3, cover and publication pages, pp. 627-633, American Academy of Allergy and Immunology, C.V. Mosby Co.
- Knobil, K., et al., "Adding salmeterol is more effective than increasing the dose of fluticasone for patients with asthma who are symptomatic on low dose fluticasone," *European Respiratory Journal*, vol. 12, Suppl. 29, Dec. 1998, pp. 19s-20s plus 1 cover page, Ref. No. P160.
- Kooreman, H. J., et al., "The synthesis of 17-esters of corticosteroids protection of 11 β -hydroxyl of the trimethylsilyl group," *Synthetic Communications*, vol. 1, No. 2, pp. 81-87, 1971, Marcel Dekker, Inc.
- Laforce, Craig F., et al., "Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents," *The Journal of Family Practice*, 1994, vol. 38, No. 2 (Feb), pp. 145-152, Appleton & Lange.
- Lane, S. J., et al., "Evaluation of a new capillary electrochromatography/mass spectrometry interface using short columns and high field strengths for rapid and efficient analyses," *Rapid Communications in Mass Spectrometry*, vol. 10, 1996, pp. 733-736, John Wiley & Sons, Ltd.
- Li, Zheng, et al., "Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under phase transfer catalysis," *Synthetic Communications*, vol. 32, No. 20, pp. 3081-3086, 2002, Marcel Dekker, Inc.
- Linder, A., "Symptom scores as measures of the severity of rhinitis," *Clinical Allergy*, 1988, vol. 18, pp. 29-37.
- Lumry, William R., "A review of the preclinical and clinical data of newer intranasal steroids in the treatment of allergic rhinitis," *J Allergy Clin Immunol*, Oct. 1999, vol. 104, No. 4, Part 1, pp. S150-S158 plus correction p. 394 dated Feb. 2000, Mosby, Inc.
- Lyseng-Williamson, Katherine A., et al., "Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease," *Am J Respir Med*, vol. 1, No. 4, 2002, pp. 273-282, Adis International Limited.
- Malhotra Exhibit A, Aug. 2011, 7 pages.
- Malhotra Exhibit B, Aug. 2011, 6 pages.
- Maus Exhibit B, Aug. 2011, 2 pages.
- May, Percy, et al., "May's Chemistry of Synthetic Drugs," Fifth Edition, 1964, pp. 12-17 plus cover and publishing pages, Longmans.
- Mealy, N. E., et al., "Ciclesonide: treatment of allergic rhinitis antiallergy/antiasthmatic," XP009041019, *Drugs of the Future*, vol. 26, No. 11, Nov. 2001, pp. 1033-1039, Prous Science.
- Meltzer, Eli O., "Allergic rhinitis: Managing the pediatric spectrum," *Allergy and Asthma Proceedings*, Jan.-Feb. 2006, vol. 27, No. 1, pp. 2-8, Oceanside Publications, Inc., U.S.A.
- Meltzer, Eli O., et al., "Onset of therapeutic effect of fluticasone

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.